Previous Close | 2.0000 |
Open | 2.1200 |
Bid | 2.0000 x N/A |
Ask | 2.0300 x N/A |
Day's Range | 2.0000 - 2.1200 |
52 Week Range | 1.8500 - 13.6500 |
Volume | |
Avg. Volume | 6,183 |
Market Cap | 31.414M |
Beta (5Y Monthly) | 1.44 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -10.4500 |
Earnings Date | Mar 26, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 31.02 |
SAN DIEGO and TORONTO, March 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the fourth quarter and year ended December 31, 2023, on Tuesday, March 26, 2024, after the close of the market, and provide a corporate update. Conference Call & Webcast: Date:Tuesday, March 26, 2024Time:5:00 PM ETAudio Webc
Assertio (ASRT) appears weighed down by the recent leadership transition. The company is also facing challenges with sales of its product franchisee of late.
SAN DIEGO and TORONTO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced the closing of the previously announced public offering (the “Public Offering”) of 5,649,122 common shares of the Company (the “Common Shares”) and warrants at a combined offering price of US $1.71 per share. This include